your market intelligence analyst
Search Results
Edit Save
358 results
Pulmonary Hypertension News 02/19/2020 13:00
Oral delivery of two proteins produced on lettuce leaves and involved in blood vessel health eased pulmonary hypertension and heart abnormalities in a rat model of pulmonary arterial hypertension (PAH). These results point to this plant-based approach as a potentially safe, inexpensive, shelf-stable treatment for PAH. Further studies are needed to confirm its benefits in […]. .
Pulmonary Hypertension News 02/11/2020 12:51
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to provide feedback on therapy development, set regulatory priorities, and contribute to patient-reported outcomes. Starting […]. .
Pulmonary Hypertension News 02/07/2020 11:30
The biopharmaceutical PhaseBio announced positive results from a case study involving a patient with pulmonary arterial hypertension (PAH) who received treatment with PB1046, a new therapy using the company’s proprietary technology platform. PB1046 is a therapy created from a combination of two other compounds: vasoactive intestinal peptide (VIP) and PhaseBio’s elastin-like polypeptide (ELP) biopolymer. Human […]. .
Pulmonary Hypertension News 02/05/2020 08:30
Seeking to further advance research into treatments for pulmonary hypertension (PH), the nonprofit Team PHenomenal Hope is now accepting submissions for its research award program. Called the PHenomenal Impact Fund for Global PH Research, the program supports investigations in basic or translational science, clinical research, and clinical need. It offers grants of $50,000 for year-long […]. .
Pulmonary Hypertension News 02/03/2020 08:00
Liquidia Technologies is requesting U.S. Food and Drug Administration (FDA) approval of LIQ861, an inhaled dry powder formulation of the vasodilator treprostinil, to treat pulmonary arterial hypertension (PAH). The request came in the form of a new drug application (NDA) to the agency. LIQ861 is based on Liquidia’s PRINT Technology, a particle engineering platform that enables the production […]. .
Pulmonary Hypertension News 01/31/2020 11:00
Treatment with sotatercept (ACE-011) eased heart strain and improved exercise capacity in individuals with pulmonary arterial hypertension (PAH) participating in the Phase 2 PULSAR trial, according to Acceleron Pharma, the therapy’s manufacturer. Sotatercept is an investigational compound designed to bind and entrap proteins from the transforming growth factor-beta (TGF-beta) family. These proteins help regulate the bone […]. .

Information Technologies

IT Markets

Business Issues

Companies - Public

Companies - Venture Funded


Analyst Firms

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications